William Blair initiated coverage of RxSight, Inc. (RXST) with a “Market Perform” rating due to stalled sales growth expected in 2025 following strong early adoption. The firm awaits evidence of sustained commercial reacceleration, despite the stock’s discounted trading. RxSight narrowed its full-year revenue guidance and is focusing on international expansion, but the article suggests greater upside potential in certain AI stocks.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
RxSight, Inc. (RXST) Initiated at Market Perform as Firm Seeks Sales Reacceleration
William Blair initiated coverage of RxSight, Inc. (RXST) with a “Market Perform” rating due to stalled sales growth expected in 2025 following strong early adoption. The firm awaits evidence of sustained commercial reacceleration, despite the stock’s discounted trading. RxSight narrowed its full-year revenue guidance and is focusing on international expansion, but the article suggests greater upside potential in certain AI stocks.